This opinion piece criticizes Health Secretary RFK Jr. for reportedly moving to reverse the FDA's 2023 safety classification of certain peptides, specifically BPC-157 and GHK-Cu. The author argues that returning these substances to a status that allows compounding pharmacies to produce them ignores the lack of clinical trial data and poses significant risks to the public.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.